Previous 10 | Next 10 |
2024-06-25 13:15:54 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk's Wegovy ge...
2024-06-25 10:45:03 ET Regis Corp. (RGS) RGS is trading UP for the last 5 days, and it at trading at $15.94 with volume of 27,015,876 and a one day change of $10.87 (214.86%). Regis Corp. has a 52-week low of 0.31 and a 52-week high of $15.24. The business's 50-day moving average pr...
2024-06-25 10:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for NVO on June 25, 2024 09:00AM ET. The previous analyst recommendation was Outperform. NVO was trading at $146.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...
2024-06-25 09:45:00 ET It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk 's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan mar...
2024-06-25 06:53:51 ET Summary Boeing offers to buy Spirit Aero for $35 per share mainly in stock. Novo Nordisk to invest $4.1B in N.C. facility for obesity drugs. Oracle warns TikTok ban in U.S. could impact earnings. Listen below or on the go on Apple Podcasts ...
2024-06-25 05:10:40 ET Novo Nordisk ( NVO ) is up 2.1 % in premarket trade after the company's Wegovy weight loss treatment was approved in the world's second-largest economy.... Read the full article on Seeking Alpha For further details see: Novo Nordisk's Wegov...
2024-06-24 14:51:58 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Lilly, Novo Nordisk to d...
2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...
2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...